Circumvent

Circumvent is developing precision medicines for neurodegenerative diseases, starting with Batten Disease, by leveraging insights into brain-cell dysfunction and palmitoylation to modulate synaptic function and lysosomal pathways. They focus on rare neurological disorders with the potential to broaden to common diseases, using a research-driven, patient-centered development approach.

The company investigates the palmitoylome and synaptome to understand brain-cell dysfunction and synaptic biology. They explore therapeutic strategies that modulate palmitoylation with the aim of affecting synaptic plasticity, neuronal differentiation, lysosomal function and autophagy, targeting Batten Disease (CLN1) and other rare neurological disorders with the goal of delivering disease-modifying treatments.

Who it’s for: Biotech/pharma companies and research-driven teams targeting rare neurological diseases, clinicians, and patient communities focused on Batten disease and related neurodegenerative conditions.

team with deep scientific and clinical background; mentions investors and partners; patient-centered approach; multiple disease focus within neurology; 2020 copyright in site